# VDK NaturaSyn

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vdk-naturasyn

- Industry: Biotechnology
- Headquarters: Baoding, China
- Website: www.vdk.com
- Total disclosed funding: $14M
- Latest round: Series A (Sep 26, 2025)
- Investors on record: 4

## About

Established in 2021 and based in Baoding, China, VDK NaturaSyn operates as a biotechnology company dedicated to biomanufacturing of natural products. It acquired certifications such as GRAS (Generally Recognized as Safe), ISO22000, FSSC2000, Kosher Certification, and Halal certification. In January 2024, VDK NaturaSyn raised approximately CNY 100 million in series A funding led by returning investor Addor Capital. In September 2025, VDK NaturaSyn closed series A+ funding from new investors CS Capital and Fortune Capital and returning investor Addor Capital.

The company is mainly based on synthetic biology technology and produces natural product functional substances through microbial cell factories. VDK NaturaSyn's products cover three fields, which are health nutrition products, natural pigments and flavours and fragrances. The products include 5-HTP Powder, Melatonin Powder, Resveratrol Powder, ß-Carotene and Zeaxanthin. The company has built four technology platforms for biosynthetic technology development and iteration.

The company generates revenue by providing biomanufacturing services for natural product health ingredients, licensing of proprietary technology.

The company will industrialize three new products, develop more products, continue to innovate technology platforms in the biomanufacturing field, and expand global business.

## Funding rounds

- Series A, Sep 26, 2025 — Fortune Capital, CS Capital, Addor Capital
- Series A, Jan 16, 2024, $14M — CDIB Capital Group, Addor Capital

## Investors

- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Fortune Capital — Series A
- CS Capital — Series A